-A A +A

Creaky Catacombs

Reported especially with your perspective and understanding of arthritis in mind. What matters most to those of us with arthritis.

VIDEO: New Data Gives Hope to the Thousands of Rheumatoid Arthritis Patients

New data has revealed that tens of thousands of rheumatoid arthritis (RA) sufferers who cannot take the current mainstay of treatment, methotrexate (MTX), are almost four times as likely to achieve disease remission from RoActemra (tocilizumab) compared to patients taking the most widely prescribed anti TNF, Humira (adalimumab).

U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis

First biologic available in both subcutaneous (SC) and intravenous (IV) formulations for the treatment of rheumatoid arthritis. Subcutaneous ORENCIA demonstrated similar efficacy (non-inferior for American College of Rheumatology [ACR] 20 responses at 6 months) to the intravenous formulation and a consistent safety profile at 6 months. The overall frequency of injection site reactions was 2.6% (19/736) and 2.5% (18/721) for the ORENCIA SC group and the ORENCIA IV group (SC placebo), respectively. The overall immunogenicity frequency to ORENCIA was 1.1% (8/725) and 2.3% (16/710) for the subcutaneous and intravenous groups, respectively. High patient retention rates (94%) were seen with the subcutaneous and intravenous formulations at 6 months.


Subscribe to RSS - Creaky Catacombs